509150-38-3

Upstream product

• 509150-37-2 ethyl 5-amino-1-(2-fluorobenzyl)-1H-indole-2-carboxylate 
• 7065-46-5 3,3-dimethylbutanoic acid chloride 
• 16732-57-3 5-nitro-indole-2-carboxylic acid ethyl ester 
• 446-48-0 o-fluorobenzyl bromide 
• 509150-04-3 ethyl 1-(2-fluorobenzyl)-5-nitro-1H-indole-2-carboxylate 

Downstream Products

• 509149-38-6 5-[(3,3-dimethylbutanoyl)-amino]-1-(2-fluorobenzyl)-N-phenyl-1H-indole-2-carboxamide 
• 904295-32-5 5-{[5-(3,3-dimethyl-butyrylamino)-1-(2-fluoro-benzyl)-1H-indole-2-carbonyl]-amino}-nicotinic acid methyl ester 
• 509149-89-7 3-({[5-[(3,3-dimethylbutanoyl)-amino]-1-(2-fluorobenzyl)-1H-indol-2-yl]-carbonyl}-amino)benzoic acid 
• 509150-40-7 5-[(3,3-dimethylbutanoyl)-amino]-1-(2-fluorobenzyl)-1H-indole-2-carboxylic acid 

Relevant academic research and scientific papers

Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis

A novel class of indole-based endothelin-converting enzyme (ECE) inhibitors was identified by high throughput screening. We report systematic optimization of this compound class by means of classical and solid-phase chemistry. Optimized compounds with a bisarylamide side chain at the 2-position of the indole skeleton exhibit low-nanomolar activity on ECE.

USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES

The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.RCK 41-Foreign Countries